Cosmetic procedures continue to rise with minimally invasive procedures accounting for the vast majority of the demand. The 2015 American Society of Plastic Surgery plastic surgery report indicates that of the 15.9 million cosmetic procedures, 14.2 million comprised of minimally invasive procedures.1 Within the cosmetic minimally invasive market, botulinum toxin type A and soft-tissue fillers represent the largest number of procedures. The purpose of this article is to provide an overview of the clinical applications, technical aspects, and future directions of neurotoxins and fillers, endeavoring to provide patients safe and successful outcomes.

**NEUROTOXINS**

Neurotoxins are products of *Clostridium botulinum* that bind to presynaptic membranes and inhibit acetylcholine release.2 This leads to reversible decrease in muscle contraction. Although various strains of botulinum toxins exist, only 3 types (onbotulinumtoxinA, BoNTA-ONA, or Botox or Botox Cosmetic [Allergan, Inc., Irvine, Calif.]; abobotulinumtoxinA, BoNTA-ABO, or Dysport [Galderma Laboratories, Lausanne, Switzerland]; and incobotulinumtoxinA Xenomin [Merz Pharma, Frankfurt am Main, Germany]) are approved by the U.S. Food and Drug Administration (FDA) for ameliorating the appearance of glabellar wrinkle lines in adults younger than 65 years of age. Botox is also approved for the treatment of crow’s feet.

All 3 neuromodulators should be treated as different products as they differ in the units per vial, composition, and efficacy per unit (Table 1).4,5 The 3 types are generally constituted in 0.9% sterile, saline (preserved and non-preserved can be used) with the reconstituted product safely stored for 1 week. The patient’s presentation and treatment areas influence the amount of the product injected. Please refer to the proper FDA labeling for details of specific use. Admittedly, all have been shown to be safe and effective for at least 3 to 4 months post treatment. These products are often employed in off-label format to treat areas outside of the glabella including the upper face, midface, and lower face (Tables 2–5).5–7 The effects of the neurotoxins last for approximately 3 to 4 months. Adverse complications can arise often because of improper techniques and lack of facial anatomy, leading to pain, inflammation, ecchymosis, erythema, and local weakness.
Table 1. Comparisons of Various Botulinum Toxin Formulations

| Brand Name (Nonproprietary Name) | FDA-approved Indications | Duration of Effect (mo) | Onset of Action (d) | % NAP to Total Protein Content | Dose Equivalent Units | Pain |
|---------------------------------|--------------------------|------------------------|-------------------|-------------------------------|----------------------|------|
| Type A                          |                          |                        |                   |                               |                      |      |
| Botox (onabotulinumtoxinA)      | Cervical dystonia        | 3–6                    | 3–5               | 85                            | 1                    | +    |
|                                 | Strabismus and blepharospasm |                      |                   |                               |                      |      |
|                                 | Rhytides: glabellar lines and crow’s feet |                  |                   |                               |                      |      |
|                                 | Severe primary axillary hyperhidrosis |            |                   |                               |                      |      |
|                                 | Upper limb spasticity    |                        |                   |                               |                      |      |
|                                 | Chronic migraines        |                        |                   |                               |                      |      |
|                                 | Neurogenic bladder       | 3–6                    | 2–4               | 0                             | 1                    | +    |
|                                 | Cervical dystonia        |                        |                   |                               |                      |      |
|                                 | Blepharospasm refractory to Botox |                  |                   |                               |                      |      |
|                                 | Rhytides: glabellar lines | 3–6                    | 3–5               | 25                            | 2–3                  | +    |
| Xeomin (incobotulinumtoxinA)    | Cervical dystonia        | 3–6                    | 2–4               | 0                             | 1                    |      |
|                                 | Rhytides: glabellar lines | 3–6                    | 3–5               | 25                            | 2–3                  | +    |
| Dysport (abobotulinumtoxinA)    | Not approved by FDA (Korea) * |                |                   |                               |                      |      |
|                                 | Cervical dystonia        | 3–6                    | 2–4               | 0                             | 1                    |      |
| Meditoxin/neuronox/Siax/Cunox/Botulift | Not approved by FDA (China) * |                |                   |                               |                      |      |
| Prostigue                       |                         |                        |                   |                               |                      |      |
| Type B                          |                         |                        |                   |                               |                      |      |
| Myobloc (rimabotulinumtoxinB)   | Cervical dystonia        | 2–3                    | 1–4               | 55                            | 30–50                | ++   |

*†Limited data available. NAP, nontoxic accessory proteins. Reprinted with permission from Plast Reconstr Surg. 2016;138:519e–530e.

---

Table 2. Consensus Recommendations and Expert Panel Opinion Regarding Combination Treatment of the Upper Face

| Frequency of Treatment with the Same vs Sequential Sessions | Typical Total Dose of OnabotulinumtoxinA (U) | Preferred Filler |
|-------------------------------------------------------------|---------------------------------------------|------------------|
| Glabellar rhytides                                          | 12–40                                       | Superficial Vycross or Hylacross Dilution-reconstitution of Hylacross preferred by some panelists |
|                                                             | Doses as low as 8 U may be appropriate for some patients |                 |
|                                                             | 8–25                                        |                  |
| Forehead                                                    |                                             |                  |
|                                                             |                                             |                  |
| Lateral periocular                                         | 6–15 per side                               |                  |

Botulinum toxin dosage recommendations may be extrapolated with care and appropriate dosages to other toxin formulations. The paradigm of layered hyaluronic acid filler implantation is illustrated by representative product selections for deep volumizer, midlevel, and superficial Vycross (Voluma, Volift, and Volbella) and for Hylacross (Juvéderm Ultra). Selections may be extrapolated as appropriate to other hyaluronic acid filler families. Reprinted with permission from Plast Reconstr Surg. 2016;137:1410–1423.

Table 3. Consensus Recommendations and Expert Panel Opinion Regarding Combination Treatment of the Middle Face

| Same vs Sequential Sessions | Typical Total Dose of OnabotulinumtoxinA (U) | Preferred Filler |
|-----------------------------|---------------------------------------------|------------------|
| Lower eyelid                | 0.5–2 per side (infraorbital rhytides)      | Supraperiosteal and subcutaneous contouring, eg, nasojugal fold: superficial Vycross Deep volumizer or midlevel Vycross |
| Nose                        | 1–4 (nasal flare) 2–6 (tip elevation) 4–8 (oblique lines). Doses as high as 10 U may be appropriate for some patients 1–6 (intracutaneous, with caution) | Deep volumizer Vycross |
| Check                       |                                             |                  |

Botulinum toxin dosage recommendations may be extrapolated with care and appropriate dosages to other toxin formulations. The paradigm of layered hyaluronic acid filler implantation is illustrated by representative product selections for deep volumizer, midlevel, and superficial Vycross and for Hylacross. Selections may be extrapolated as appropriate to other hyaluronic acid filler families. Reprinted with permission from Plast Reconstr Surg. 2016;137:1410–1423.
Technical Pearls

- Avoid injecting into the lower aspect of the midbrow to prevent diffusion into the levator muscle causing eyelid ptosis.
- Lateral corrugators must be injected 1 to 2 cm above the orbital rim to avoid the Mephistos sign (quizzical look).
- Crow’s feet must be injected superficially (subdermal), 1 cm lateral to the orbital rim, and above the zygoma to avoid diplopia, ectropion, and ecchymosis.
- The perioral region must be injected in small volumes to avoid oral incompetence and speech pathology. This must be done with a profound understanding of the perioral anatomy including the depressor anguli oris.
- Platysma bands should be in small amounts and superficially into the specific platysmal bands only (no more than 100 U Botox in 1 setting) to avoid dysphagia.

Future Directions

In 2000, the first open-label, noncontrolled trial demonstrated BoNTA-ONA as a safe and efficacious modality for acute and prophylactic treatment of migraine headaches. Since then, numerous studies have highlighted the benefit of BoNTA-ONA in addressing chronic migraines.8-12 The International Headache Classification 3rd Edition (Beta Version) defines chronic migraine as a headache occurring on at least 15 days per month for more than 3 months, with features of migraine headaches on at least 8 days a month.13 BoNTA-ONA has also been used in headaches associated with cervical dystonia and tension type and with whiplash, but its role is not as well defined as in chronic migraines.

Furthermore, the use of Microbotox, a technique that involves tiny blebs of Microbotox, refers to the use of a neuromodulator at 0.8- to 1.0-cm intervals into the skin or just below that into the superficial fibers of the facial muscles.14,15 The purpose is to weaken the superficial muscles, leaving the underlying deeper facial muscles alone. It has been found that this can smoothen and tighten the skin.

The technique has been utilized successfully in the upper face and midface16 and recently in lower face and neck.14 It also provides the ability to control sweat and sebaceous glands, providing a smoother skin.15 Studies have confirmed Botox as modality to treat palmar hyperhidrosis.
Neurotoxins are being developed including a topical form with clinical trials underway that may obviate the need for injections in specific areas and potentially reduce pain from shots. These products are being trialed for lateral crow’s feet, glabellar lines, and hyperhidrosis. Currently, Revance (Newark, Calif.) is conducting clinical trials with its products, RT001 and RT002 (topical BoNTA-ONA), to be used for crow’s feet and axillary hyperhidrosis and glabellar lines and cervical dystonia, respectively. Although 1 study does demonstrate favorable treatment of crow’s feet using RT001, further scientific data are needed to determine its efficacy in other areas. Other type A products including the Korean versions (Meditoxin/Siax/Neuronox) and Prosigne (Lanzhou Institute of Biological Products, Lanzhou, People’s Republic of China) are currently not approved by the FDA but may be in the future pending future trials.

FILLERS

Although various dermal fillers exist, the focus of this article is on the following: hyaluronic acid (HA) products, calcium hydroxyapatite, poly-l-lactic acid, and poly-methylmetacrylate. The rise in filler use may be attributable to the paradigm shift from a 2-dimensional view to a 3-dimensional perception of the face, with aging impacting tremendously in the medial aspect by volume loss. In fact, many cosmetic medicine practitioners are adhering to the mantra of lift laterally and fill medially, acknowledging the profound rejuvenation effect that occurs when placing volume in areas such as the tear trough, malar projection, nasolabial fold, and lips. The powerful combination of neuromodulator and filler therapy can treat hyperdynamic muscle changes and volume loss, restoring facial harmony in the early signing of facial aging.

Currently, there is an evolving family of FDA-approved HA products such as Restylane and Restylane Lyft (Galderma Laboratories, Fort Worth, Tex.), Belotero (Merz Aesthetics, Greensboro, N.C.); and Juvederm Ultra, Juvederm Voluma, and Vobella (Allergan, Irvine, Calif.). HA products arise from various areas by altering their biological composition. As collagen necessitates a skin test 1 month before its use to determine if allergic symptoms will develop.

These properties determine how much and where in the face these fillers are employed. Various techniques exist in how to inject them including serial puncture, threading, fanning, and cross-hatching. The type of product impacts how it is injected, where it is injected, and what quantity is injected (Table 5). For example, high-viscous and densely cross-linked substances such as Juvederm Voluma and Restylane Lyft are used for malar augmentation, whereas less viscous and lower cross-linked substances such as Belotero, Restylane Silk, and Vobella when injected in a smooth manner can be used for fine lines, wrinkles, and lip augmentation (Tables 2–5).

Technical Pearls

- Profound understanding of the facial anatomy as it relates to the vasculature is paramount in delivering fillers safely to avoid catastrophic insults, such as blindness and nasal tip necrosis.
- Specific training is essential for each filler and for each area especially for around the nose, lips, and periorbital areas to prevent significant adverse reactions and vascular consequences.
- Fillers can be used conservatively, advising patients that touch-ups will be necessary to avoid overfilling areas.
- Recognize vascular compromise signs such as blanching and abort procedure; be familiar with application of nitropaste and injection of hyaluronidase.

Future Directions

The use of safe and more versatile FDA-approved fillers for restoring volume outside the face as well as for roles outside of volume expansion continues to expand. Recent articles have demonstrated its utility in hand rejuvenation when injected using the appropriate technique. Its role in acne continues to be under investigation with further studies necessary. Others have reported its role in chin implants as fillers can soften the transition from the skin to the implant with its volume effect. It can also provide volume to areas for the ear lobe, addressing sagging effects.

Manufacturers continue to develop fillers to utilize in various areas by altering their biological composition. As the search for a product that is nonimmunogenic, biodegradable, reversible, and long-lasting, the creation of new fillers and their uses continue to evolve.
CONCLUSIONS

Neurotoxins and fillers remain the highest demanded comestic minimally invasive procedures. Their combined use provides an injector powerful ways to reverse the stigmata of aging, particularly facial hyperdynamic musculature and volume loss. The role they play in other areas outside of the face and treatment of other disorders continues to evolve with further scientific studies need to validate claims. This article endeavors to provide a reference of the use of neumodulators and fillers, technical maneuvers to mitigate complications, and future directions.

Jeanine B. Downie, MD
Image Dermatology P.C.
51 Park Street
Montclair, NJ 07042
E-mail: jeaninedownie@yahoo.com

Anup Patel, MD, MBA
Orlando Plastic Surgery Institute
Orlando, FL 32804
E-mail: dranupprpa@gmail.com

REFERENCES

1. The American Society of Plastic Surgeons Annual National Clearinghouse Statistics. Available at: http://www.plasticsurgery.org. Accessed October 1, 2016.
2. Gart MS, Gutowski KA. Aesthetic uses of neuromodulators: current uses and future directions. Plast Reconstr Surg. 2015;136(5 Suppl):62S–71S.
3. Kordestani R, Small KH, Rohrich RJ. Advancements and refinement in facial neuromodulators. Plast Reconstr Surg. 2016;138:803–806.
4. Manstein CH, Beidas OE. Comparing clinical efficacy of botulinum toxin and dysport in a small group of patients. Plast Reconstr Surg. 2011;128:26e–27e.
5. Noland ME, Lalonde DH, Yee GJ, et al. Current uses of botulinum neurotoxins in plastic surgery. Plast Reconstr Surg. 2016;138:519e–530e.
6. Sundaram H, Liew S, Signorini M, et al; Global Aesthetics Consensus Group. Global aesthetics consensus: avoidance and optimization of complications from hyaluronic acid fillers—evidence- and opinion-based review and consensus recommendations. Plast Reconstr Surg. 2016;137:961e–971e.
7. Glogau RG. Treatment of palmar hyperhidrosis with botulinum toxin. Semin Cutan Med Surg. 2001;20:101–108.
8. Glogau R, Blitzer A, Brandt F, et al. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol. 2012;11:38–45.
9. Wilson AJ, Taglienti AJ, Chang CS, et al. Current applications of facial volumization with fillers. Plast Reconstr Surg. 2016;137:872e–889e.
10. Diener HC, Dodick DW, Aurora SK, et al; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804–814.
11. Janis JE, Barker JC, Javadi C, et al. A review of current evidence in the surgical treatment of migraine headaches. Plast Reconstr Surg. 2014;134:131S–41S.
12. Lipton RB, Varon SF, Grosberg B, et al. OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 2011;77:1465–1472.
13. Torelli P, Jensen RH, Tavaniqpour D, et al. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;53:137–146.
14. Wu WT. Microbotox of the lower face and neck: evolution of a personal technique and its clinical effects. Plast Reconstr Surg. 2015;136(5 Suppl):92S–100S.
15. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001;323:596–599.
16. Wu WTL. Facial and lower limb contouring. In: Benedetto AV, ed. Botulinum Toxins in Clinical Aesthetic Practice. 2nd ed. New York: Informa Healthcare; 2011:206–222.
17. Glogau RG. Treatment of palmar hyperhidrosis with botulinum toxin. Semin Cutan Med Surg 2001;20:101–108.
18. Glogau R, Blitzer A, Brandt F, et al. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J Drugs Dermatol. 2012;11:38–45.
19. Wilson AJ, Taglienti AJ, Chang CS, et al. Current applications of facial volumization with fillers. Plast Reconstr Surg. 2016;137:872e–889e.
20. Costa CR, Kordestani R, Small KH, et al. Advances and refinement in hyaluronic acid facial fillers. Plast Reconstr Surg. 2016;138:233e–236e.
21. Sykes JM, Cotofana S, Trevidic P, et al. Upper face: clinical anatomy and regional approaches with injectable fillers. Plast Reconstr Surg. 2015;136:204S–218S.
22. Rohrich RJ, Ghavami A, Crosby MA. The role of hyaluronic acid fillers (Restylane) in facial cosmetic surgery: review and technical considerations. Plast Reconstr Surg 2007;120(6 Suppl):A1S–54S.
23. Signorini M, Liew S, Sundaram H, et al; Global Aesthetics Consensus Group. Global aesthetics consensus: avoidance and management of complications from hyaluronic acid fillers—evidence- and opinion-based review and consensus recommendations. Plast Reconstr Surg. 2016;137:961e–971e.
24. Gargass SS, Carbone MC. Hand rejuvenation using Radiesse. Plast Reconstr Surg. 2010;125:296e–296e.
25. Lefebvre-Vilardebo M, Trevidic P, Moradi A, et al. Hand: clinical anatomy and regional approaches with injectable fillers. Plast Reconstr Surg. 2015;136(5 Suppl):258S–275S.
26. Carruthers JD, Glogau RG, Blitzer A; Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies—consensus recommendations. Plast Reconstr Surg. 2008;121(5 Suppl):S5–S30S; quiz 31S.